SEARCH

SEARCH BY CITATION

References

  • 1
    Crabb DW, Lumeng L. Alcoholic liver diseases. In: YamadaT, AlpersDH, KaplowitzN, LaineL, OwyangC, PowellDW, eds. Textbook of Gastroenterology, Volume 2. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003; 24152436.
  • 2
    Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch 2004; 444: 312.
  • 3
    Brunt E, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 4
    Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246258.
  • 5
    Ishii H. Common pathogenic mechanisms in ASH and NASH. Hepatol Res 2003; 28: 1820.
  • 6
    Ghoshal AK, Farber E. Choline deficiency, lipotrope deficiency and the development of liver disease including liver cancer: a new perspective. Lab Invest 1993; 68: 255260.
  • 7
    Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 17741783.
  • 8
    Fan C-Y, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1998; 273: 1563915645.
  • 9
    Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398403.
  • 10
    Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 11251131.
  • 11
    Reddy JK. Peroxisome proliferators and peroxisome proliferator-activated receptor α. Biotic and xenobiotic sensing. Am J Pathol 2004; 164: 23052321.
  • 12
    Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649688.
  • 13
    Rosen ED, Spiegelman BM. PPARγ: A nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem 2001; 276: 3773137734.
  • 14
    Jia Y, Qi C, Kashireddi P, Surapureddi S, Zhu Y-J, Rao MS, et al. Transcriptional coactivators PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARα-regulated gene expression in liver. J Biol Chem 2004; 279: 2442724434.
  • 15
    Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995; 15: 30123022.
  • 16
    Peters JM, Cattley RC, Gonzalez FJ. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator WY-14,643. Carcinogenesis 1997; 18: 20292033.
  • 17
    Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000; 275: 2891828928.
  • 18
    Kersten, S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest 1999; 103: 14891498.
  • 19
    Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123132.
  • 20
    Kashireddy PV, Rao MS. Lack of peroxisome prolifertor-activated receptor α in mice enhances methionine and choline deficient diet-induced steatohepatitis. Hep Res 2004. In press.
  • 21
    Rao MS, Kashireddy P, Musunuri S, Okonkwo A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator activated receptor α ligand in rats. In Vivo 2002; 16: 145152.
  • 22
    Ip E, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 12861296.
  • 23
    Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K Fukushima Y, et al. Peroxisome proliferator activated receptor α (PPARα) protects against alcohol-induced liver damage. Hepatology 2004; 40: 972980.
  • 24
    Nanji AA, Danneberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-activated receptor-α (PPARα)-regulated genes and is ameliorated by PPARα activation. J Pharmacol Exp Ther 2004; 310: 417424.
  • 25
    Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor α (PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278: 2799728004.
  • 26
    Tsukamato H, Towner SJ, French SW. Ethanol-induced liver fibrosis in rats fed high fat diets. Hepatology 1986; 6: 814822.
  • 27
    Palmer CAN, Hsu M, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 1998; 53: 1422.
  • 28
    Jia Y, Qi C, Kashireddi P, Surapureddi S, Zhu YJ, Rao MS, et al. Transcription coactivator PBP, the peroxisome proliferator-activated receptor α (PPARα)-binding protein, is required for PPARα-regulated gene expression in liver. J Biol Chem 2004; 279: 2442724434.